UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): July 18, 2011


                                 BIOCUREX, INC.
                         -------------------------------
             (Exact name of Registrant as specified in its charter)


      Texas                           0-269471               75-2742601
--------------------           ---------------------   ------------------------
(State or other jurisdiction    (Commission File No.)       (IRS Employer
of incorporation)                                          Identification No.)

                           7080 River Road, Suite 215,
                  Vancouver, British Columbia, Canada, V6X 1X5
               --------------------------------------------------
          (Address of principal executive offices, including Zip Code)


Registrant's telephone number, including area code:    (866) 884-8669

                                       N/A
                      -----------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant  to  Rule  13e-14(c)  under  the
Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 5.02.  Departure of Directors of Certain  Officers;  Election of Directors;
            Appointment of Certain  Officers; Compensatory Arrangement of
            Certain Officers.

     On July 18, 2011 the Company  appointed Paul D. Slowey,  Ph.D. as President
and a Director and appointed Trent Davis as a Director.

     Dr. Paul Slowey (age 55) has been President and Chief Executive  Officer of
Oasis Diagnostics  Corporation since 2007 and Managing Member of Bamburgh Marrsh
LLC since 2002.  Previously  he held  various  diagnostic  positions  including;
Director of International Sales for OraSure (formerly Epitope),  Chief Operating
Officer  for Saliva  Diagnostics,  Director of  International  Sales for Incstar
Corp.  [now  DiaSorin].  He holds a B.S.  (Honors)  from  Sheffield  Polytechnic
(England),   a   Ph.D.   in   Organic   Chemistry   from   the   University   of
Newcastle-Upon-Tyne  (England) and Post-Doctoral  Fellowships from University of
Victoria and Memorial University of Newfoundland (Canada).

     As President,  Dr. Slowey will be responsible  for marketing and management
of the  Company's  OncoPet  Diagnostics  Division  and  supporting  the  broader
licensing  efforts of the Company.  Dr.  Slowey  served as the  Company's  Chief
Executive  Officer during 2001-2002 and has been a consultant to the Company for
the past three years.

     Trent Davis (age 43) has been with Paulson Investment  Company,  Inc. since
1991 and has served as Paulson's  President  and Chief  Executive  Officer since
2005.  Prior to being  appointed as President and Chief Executive  Officer,  Mr.
Davis served as Senior Vice President of Paulson's  Syndicate  Department.  From
2001 to 2005 Mr.  Davis  served  as a board  member of the  National  Investment
Banking  Association  and from 2003 to 2004 Mr. Davis served as Chairman of that
association.  Mr. Davis holds a B.S. in Business  and  Economics  from  Linfield
College  and  earned a  Master's  Degree  in  Business  Administration  from the
University of Portland.

     As head of the Syndicate  Department for Paulson financings,  Mr. Davis was
intimately  involved  in the  financing  of the  Company in January  2010.  As a
Director,  Mr. Davis brings extensive experience in capital markets and investor
relations to the Company.

     As of July 18,  2011 Dr.  Slowey  did not own any  shares of the  Company's
common stock.

     As of July 18, 2011 Mr. Davis owned 20,000 shares of the  Company's  common
stock.  These shares represent 0.01% of the Company's  outstanding  shares as of
July 18, 2011. As of July 18, 2011 Mr. Davis also owned warrants which allow Mr.
Davis to purchase up to 200,000 shares of the Company's  common stock at a price
of $0.107 per share. The warrants expire on January 19, 2015.

                                       2

<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  July 22, 2011

                                 BIOCUREX, INC.


                                 By: /s/ Ricardo Moro
                                     ---------------------------
                                     Dr. Ricardo Moro, President

                                       3

<PAGE>
[{"type": "8-K", "sequence": "1", "filename": "form8kitem502july-11.txt", "description": "FORM 8-K ITEM 5.02 JULY 18, 2011", "secsgml_size_bytes": 5428}]
{"company-data": {"conformed-name": "BIOCUREX INC", "cik": "0001092562", "assigned-sic": "3841", "irs-number": "752742601", "state-of-incorporation": "A1", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26947", "film-number": "11983032"}, "business-address": {"street1": "7080 RIVER RD", "street2": "STE 215", "city": "RICHMOND", "state": "A1", "zip": "V6X 1X5", "phone": "6042079150"}, "mail-address": {"street1": "7080 RIVER RD", "street2": "STE 215", "city": "RICHMOND", "state": "A1", "zip": "V6X 1X5"}, "former-company": {"former-conformed-name": "WHISPERING OAKS INTERNATIONAL INC", "date-changed": "19990804"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): July 18, 2011

                                 BIOCUREX, INC.
                         -------------------------------
             (Exact name of Registrant as specified in its charter)

      Texas                           0-269471               75-2742601
--------------------           ---------------------   ------------------------
(State or other jurisdiction    (Commission File No.)       (IRS Employer
of incorporation)                                          Identification No.)

                           7080 River Road, Suite 215,
                  Vancouver, British Columbia, Canada, V6X 1X5
               --------------------------------------------------
          (Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code:    (866) 884-8669

                                       N/A
                      -----------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement  communications  pursuant  to  Rule  13e-14(c)  under  the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02.  Departure of Directors of Certain  Officers;  Election of Directors;
            Appointment of Certain  Officers; Compensatory Arrangement of
            Certain Officers.

     On July 18, 2011 the Company  appointed Paul D. Slowey,  Ph.D. as President
and a Director and appointed Trent Davis as a Director.

     Dr. Paul Slowey (age 55) has been President and Chief Executive  Officer of
Oasis Diagnostics  Corporation since 2007 and Managing Member of Bamburgh Marrsh
LLC since 2002.  Previously  he held  various  diagnostic  positions  including;
Director of International Sales for OraSure (formerly Epitope),  Chief Operating
Officer  for Saliva  Diagnostics,  Director of  International  Sales for Incstar
Corp.  [now  DiaSorin].  He holds a B.S.  (Honors)  from  Sheffield  Polytechnic
(England),   a   Ph.D.   in   Organic   Chemistry   from   the   University   of
Newcastle-Upon-Tyne  (England) and Post-Doctoral  Fellowships from University of
Victoria and Memorial University of Newfoundland (Canada).

     As President,  Dr. Slowey will be responsible  for marketing and management
of the  Company's  OncoPet  Diagnostics  Division  and  supporting  the  broader
licensing  efforts of the Company.  Dr.  Slowey  served as the  Company's  Chief
Executive  Officer during 2001-2002 and has been a consultant to the Company for
the past three years.

     Trent Davis (age 43) has been with Paulson Investment  Company,  Inc. since
1991 and has served as Paulson's  President  and Chief  Executive  Officer since
2005.  Prior to being  appointed as President and Chief Executive  Officer,  Mr.
Davis served as Senior Vice President of Paulson's  Syndicate  Department.  From
2001 to 2005 Mr.  Davis  served  as a board  member of the  National  Investment
Banking  Association  and from 2003 to 2004 Mr. Davis served as Chairman of that
association.  Mr. Davis holds a B.S. in Business  and  Economics  from  Linfield
College  and  earned a  Master's  Degree  in  Business  Administration  from the
University of Portland.

     As head of the Syndicate  Department for Paulson financings,  Mr. Davis was
intimately  involved  in the  financing  of the  Company in January  2010.  As a
Director,  Mr. Davis brings extensive experience in capital markets and investor
relations to the Company.

     As of July 18,  2011 Dr.  Slowey  did not own any  shares of the  Company's
common stock.

     As of July 18, 2011 Mr. Davis owned 20,000 shares of the  Company's  common
stock.  These shares represent 0.01% of the Company's  outstanding  shares as of
July 18, 2011. As of July 18, 2011 Mr. Davis also owned warrants which allow Mr.
Davis to purchase up to 200,000 shares of the Company's  common stock at a price
of $0.107 per share. The warrants expire on January 19, 2015.

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  July 22, 2011

                                 BIOCUREX, INC.

                                 By: /s/ Ricardo Moro
                                     ---------------------------
                                     Dr. Ricardo Moro, President

                                       3